While immune checkpoint inhibitors can block PD-L1/PD1 signaling and reactivate T-cell immunity, we postulate that they might also have direct cytotoxic effects toward neoplastic B cells in CLL and RS, much more pronounced in the latter due to higher expression of PD-L1/PD1. This evidence concerns the gene CD274 and B-cell chronic lymphocytic leukemia.